BCTG SEC filings, in plain English
Everything BCTG Acquisition Corp. has filed with the SEC that we hold — 40 filings, newest first, 6 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Tango Therapeutics, Inc. (Nasdaq: TNGX) reported under Item 8.01 that it has expanded its at-the-market equity program under the November 21, 2025 sales agreement with Leerink Partners. The prior prospectus supplement covered up to $100,000,000 of common stock, of which approximately $64,389,566 has been sold to date and approximately $35,610,434 remains unsold. Why it matters: The at-the-market capacity rises from about $35.6 million remaining to $400 million in total, roughly a fourfold increase on the original programme — dilution capacity the company can draw on at its sole discretion without a further shareholder vote. The $64.4 million already sold is disclosed on the record.
What changed: Tango Therapeutics reported Q2 2026 results with $1.0B cash position as of June 30, 2026, up from $399M at year-end 2025, and a net loss of $55.3M ($0.37/share) for the quarter. The company reported positive Phase 1/2 data showing 92% ORR for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer and plans to advance to Phase 3. Why it matters: The significant cash increase and strong Phase 1/2 data position Tango for late-stage clinical development of vopimetostat in pancreatic cancer, with Phase 3 trial design expected in 2H 2026. The company's cash runway supports planned development and commercialization preparation.
What changed: ... Why it matters: ...
What changed: BCTG Acquisition Corp. filed an 8-K/A on 2026-08-07 disclosing a separation agreement between Tango Therapeutics and Executive Chairman Barbara Weber, effective 2026-08-06, with severance benefits and continuing obligations. Why it matters: This is a post-close executive departure at the combined company, with no impact on trust value, redemption deadlines, or SPAC mechanics; it is purely an employment/separation matter.
What changed: Dr. Barbara Weber's employment as Executive Chair of Tango Therapeutics ended on August 3, 2026, per her Employment Agreement dated January 8, 2026, with resignation from all officer and board positions. The company offered severance through December 31, 2026, COBRA reimbursement, 12-month equity vesting acceleration, and extended option exercise to August 3, 2027. Why it matters: This is a post-close leadership departure at the former BCTG target, indicating a governance transition. The structured separation package suggests an amicable, pre-planned exit rather than a dispute-driven departure.
What changed: Item 5.02: on June 19, 2026 the board of Tango Therapeutics increased its size to seven directors and appointed Robert Azelby to fill the new vacancy, effective that date. He is a Class II director until the 2029 annual meeting. The board determined he is independent under Nasdaq listing standards and appointed him to the compensation committee and the nominating and corporate governance committee effective June 23, 2026. Under the non-employee director compensation program he receives a stock option for 35,910 shares at an exercise price of $27.97 per share plus a restricted stock award. Why it matters: For a post-de-SPAC company, board expansion with an independent director who joins both the compensation and nominating committees strengthens the governance profile that public shareholders inherited from the SPAC structure. The disclosed option exercise price of $27.97 is a dated reference point for where the shares traded on June 19, 2026, which is useful context for anyone tracking the company's performance since the business combination. No financial results or transactions are reported.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.